A charity has announced the launch of the first motor neurone disease (MND) clinical drug trial in Scotland, in over 20 years.
MND Scotland, which is spending £1.5m on drug trials, will test a new therapy for the most common form of MND.
The first trial for Amyotrophic Lateral Sclerosis (ALS) involves Interleukin-2, which is used for some types of cancer.
The study will focus on types of immune cells in the blood, which can influence the speed at which ALS progresses.
This is because these immune cells are believed to play a part in protecting the motor neurones, the nerve cells that control movement.
‘Important first step’
MND Scotland is now recruiting patients in Glasgow who meet the criteria for tests.
Dr George Gorrie, consultant neurologist at Queen Elizabeth University Hospital, who will be leading the trial in Scotland, said: “This is an important first step in providing patients with MND the opportunity to take part in therapeutic studies in Scotland.
Read more at: https://www.bbc.co.uk/news/uk-scotland-45097307